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Abstract
Emergent coronary reperfusion therapies are rarely carried out before considerable myocardial
injury has occurred.

Moreover, reperfusion after prolonged ischemia produces paradoxical

ischemia-reperfusion injury, attenuating the efficacy of reperfusion therapies.

This has provided

impetus for identifying chronic therapies to protect against ischemia-reperfusion injury in those at
risk.

We previously found regular dipyridamole therapy produces a chronic preconditioning-like

effect mediated through adenosine A1 receptors. To determine how long this chronic
preconditioning effect of dipyridamole remains present after discontinuing therapy, guinea pigs
received 4 mg/kg/day in their water for 6 weeks. Ischemia-reperfusion was performed at 0, 2, 3, and
4 days after dipyridamole discontinuation (0Day, 2Days, 3Days and 4Days; n=8 per group).

Left

ventricular developed pressure (LVDP), end-diastolic pressure (LVED), coronary flow (CF), infarct
size, and western blot analyses for Akt and endothelial nitric oxide synthase (eNOS) were studied.
After ischemia-reperfusion, 0Day, 2Days and 3Days, but not 4Days, had significantly higher LVDP
and lower LVDEP compared to control. Myocardial infarct size was significantly reduced at 0Day,
2Days and 3Days, but not 4Days, compared to control. Western blot analyses demonstrated
upregulation of phospho-Akt and phospho-eNOS expression at 0Day, 2Days, 3Days, but not 4Days.
A chronic preconditioning-like cardioprotection by regular dipyridamole treatment persists for 3
days after discontinuing therapy. Increased activated Akt and eNOS expression may play a role in
this persistent cardioprotection.

The Persantine-Aspirin Reinfarction Study (PARIS) Research Group examined the efficacy of
Persantine (dipyridamole 75 mg) in combination with aspirin (324 mg) versus aspirin alone or
placebo for preventing reinfarction in 2026 patients with a prior history of myocardial infarction in
the preceding 8 weeks to 5 years[1]. No significant differences were observed between
dipyridamole plus aspirin versus aspirin alone in total mortality, coronary mortality, or nonfatal
myocardial infarction (MI). However, patients were followed from 1975 to 1979, before
revascularization procedures were widely available. Follow up studies and meta-analyses also
supported the lack of benefit of adding dipyridamole to aspirin to prevent cardiovascular events,
with the possible exception of strokes in at risk patients.

Acute MI’s are now routinely treated with emergent reperfusion therapies. However, these
reperfusion therapies are rarely carried out before considerable myocardial injury has occurred.
Moreover, reperfusion after prolonged ischemia produces a paradoxical ischemia-reperfusion
injury[2,3], potentially attenuating the efficacy of reperfusion therapies.

This has provided

impetus for identifying therapies which protect against ischemia-reperfusion injury.

Acute

interventions, including ischemic preconditioning and infusion of adenosinergic agents (including
dipyridamole)[2-4], reduce ischemia-reperfusion injury in animal models and human myocardium.
To date, continual protection against ischemia-reperfusion injury is not available for patients at high
risk for MI who may require emergent reperfusion therapy.

Several lines of evidence suggest that nucleoside transport inhibitors, which increase extracellular
adenosine levels by inhibiting uptake into myocytes and endothelial cells, might offer sustained or
chronic protection against ischemia-reperfusion injury.

We previously demonstrated that chronic

exposure to ethanol, an adenosine uptake inhibitor, reduces ischemia-reperfusion injury in guinea

pig hearts, requiring adenosine A1 receptor signaling and εPKC translocation within the myocyte to
effect cardioprotection[5,6]. While mechanistically interesting, the search for a safer therapy against
ischemia-reperfusion injury was necessary. We subsequently found that regular dipyridamole
therapy, a clinically usable nucleoside transport inhibitor, induces similar continual cardioprotection
to that seen with chronic ethanol exposure, also mediated through adenosine A1 receptor
activation[7].

As dipyridamole is clinically available, we asked whether chronic therapy with this adenosine
uptake inhibitor produces continued protection against ischemia-reperfusion injury that lasted
beyond 24 hours after the last dosing. We further sought to identify potential mechanisms
underlying this sustained cardioprotective effect.

We found that regular dipyridamole therapy

protects against ischemia-reperfusion injury, a protective effect persisting for at least 3 days
following the last dosing. This sustained protection was associated with continued increased
expression of activated Akt and endothelial nitric oxide synthase (eNOS), known mediators of
myocyte preconditioning signaling cascades.

Materials and Methods
This study was conducted in accordance with the Guidelines for Animal Research at Osaka
Dental University, and with the approval of the Animal Experiment Committee of Osaka Dental
University, Osaka, Japan. These guidelines conform with the Guide for the Care and Use of
Laboratory Animals from the National Academy of Sciences, Washington D.C, USA. Male Hartley
guinea pigs were fed Lab Diet (RC4, Oriental Yeast, Tokyo, Japan) and given water ad libitum.
Dipyridamole was added to the drinking water of the dipyridamole-treated guinea pigs (11.4 mg/l)
for 6 weeks. Guinea pigs drink approximately 3.5 ml water per 10 g of body weight per day,
resulting in a dipyridamole intake of 4mg/kg/day. This dose approximates the daily human dose of
75–100 mg four times daily. A diagram of the experimental protocol is shown in Figure 1.

Isolated Heart Perfusion and Measurement of Function
Male guinea pigs weighing 550-700g (12-13 weeks old) were given heparin (1000 units
intraperitoneally), then anesthetized with pentobarbital (60 mg/kg, intraperitoneally). Hearts were
excised and immediately arrested in cold iso-osmotic saline containing 20 mM KCl. The aorta was
cannulated and the isolated hearts were perfused at 70 mmHg on a nonrecirculating isovolumic
perfused heart apparatus, using a Krebs-Henseleit perfusate and paced at 240 beats/min as
previously described.[5]

Left ventricular developed pressure (LVDP; mmHg) was measured

using a 2.5 French, high-fidelity micromanometer (Nihon-Kohden, Tokyo, Japan) passed into a
compliant latex balloon, inserted into the left ventricle, and recorded on a PowerLab 2/20 Data
Recording System (ADInstruments, Hayward, Australia). The balloon was connected to a
Y-adapter with one end used to advance the micromanometer and the other used to fill the left
ventricular balloon with bubble-free water to an end-diastolic pressure (LVEDP) of 10 mmHg.
Coronary flow (CF) (ml/min) was measured by collecting effluent. Global ischemia was achieved
by clamping the aortic inflow line. During ischemia, hearts were maintained at 37 °C by enclosure

in a water-jacketed air chamber. Warmed perfusate kept in the lower part of the chamber saturated
the air with humidity and prevented cooling by evaporation. Heart temperature was continuously
monitored by a digital thermometer (PTW-100A, Unique Medical, Tokyo, Japan).

Experimental Protocol
Forty guinea pigs were divided into 5 groups of eight each (see Figure 1). After a 20 min
equilibration, baseline LVDP, LVEDP and CF were recorded. Eight hearts were subjected to 30
min of ischemia followed by 120 min of reperfusion (control; CTL). Ischemia-reperfusion was
performed at 0, 2, 3, and 4 days after discontinuation of dipyridamole in four additional groups of
eight each (0Day, 2Days, 3Days and 4Days).

Determination of Myocardial Infarct Size
At the end of experiments, hearts were quickly frozen at –80 °C for 15 min, and then sliced
into 2 mm thick transverse sections from apex to base (6 slices/heart). After removing the right
ventricle and defrosting, each slice was weighed and incubated at 37 °C with 1%
triphenyltetrazolium chloride (Sigma Chemicals) in phosphate buffer (pH 7.4) for 10 min and then
fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from pale unstained
necrotic tissue.[8] Each slice was photographed and the necrotic area was determined using Adobe
Photoshop® CS (Adobe, San Jose, CA, USA) and multiplied by the weight of the slice, then
expressed as a fraction of the left ventricle.

Western Blot Analysis
Separate experiments were performed on eight additional hearts to examine expression of Akt
and eNOS (n=4 for each group). Myocardial tissue samples were collected after 120min reperfusion,

and homogenized in ice-cold homogenizing buffer containing 250 mM sucrose, 20 mM HEPES (pH
7.5), 10 mM KCl, 2 mM EGTA, 2 mM MgCl2, 25 mM NaF, 50 mM β-glycerophosphate, 1 mM
Na3VO4, 1mM PMSF and protease inhibitor leupeptin (10 µg/ml). The homogenate was centrifuged
at 1000g for 5 min at 4 °C to clean up. The supernatant was re-centrifuged at 10000g for 15 min at 4
°C to obtain cytosolic fraction. The protein concentration was estimated with a Bradford assay.
Equivalent amounts (20 µg) of protein samples were loaded and separated on a 10% SDS-PAGE
gradient gel, then electrically transferred overnight to a polyvinylidene difluoride membrane
(Bio-Rad, Hercules, CA, USA). After blocking with 5% skim milk in Tris-buffered saline containing
0.1% Tween-20 (TBS-T), the membranes were incubated for 2 h at 4 °C in TBS-T containing 5%
skim milk and overnight 1:1000 dilution of rabbit primary antibody for phospho-Akt (Ser437; Cell
Signaling Technology, Boston, MA), and phospho-eNOS (Ser177; Cell Signaling Technology,
Boston, MA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase–labeled
anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, Buckinghamshire, United Kingdom). The
same blot was stripped and re-blotted with antibodies to total-Akt, total-eNOS (Cell Signaling
Technology, Boston, MA) and α -tubulin (Santa Cruz Biotechnology) to confirm equal protein
loading. Bound antibody signals were detected with enhanced chemiluminescence (Pierce
Biotechnology, Rockford, IL) and visualized using VersaDoc 5000 Imaging System (Bio-Rad,
Hercules, CA, USA). Quantitative analysis of the band densities was performed by Quantity One
software (Bio-Rad), and the results are presented as the ratio of phospho-Akt and phospho-eNOS to
total Akt and eNOS. The average light intensity was multiplied by 100 to facilitate presentation of an
x-fold increase.

Statistical Analysis
All data are expressed as mean±SD. Statistical power analysis revealed that a sample size of
n=8 per group would provide sufficient power (0.8) to detect a difference between mean infarct size

indices of 15 % (SD=9, α=0.05). A group size of n=4 was used for Western blot to provide a power
of 0.8 to detect a difference between means of 20% (SD=10, α=0.05). Hemodynamic data were
tested for normal distribution and subsequently analyzed by a two-factor repeated-measures
analysis of variance for time and treatment. If an overall difference between the variables was
observed, comparisons were performed as one-way ANOVA followed by Tukey's post-hoc test for
inter-group differences and by Dunnett's for intra-group differences with baseline values as the
reference time point. Analyses of infarct size and Western blot were performed using one-way
ANOVA followed by Student's t-test with Bonferroni's correction for multiple comparisons to
avoid type I error. For changes within and between groups a two-tailed p value less than 0.05 was
considered significant in advance. (SPSS17 for Windows, SPSS Japan, Tokyo, Japan).

RESULTS

Regular Dipyridamole Therapy Improves Contractile Recovery During Post-Ischemic Reperfusion.
Baseline LVDP, LVEDP and coronary flow were similar in perfused hearts from animals treated for
six weeks with dipyridamole and age-matched controls (Table 1).

LVDP recovery was

significantly improved during post-ischemic reperfusion in hearts from animals treated with
dipyridamole for 6 weeks compared to controls at 0Day, 2Days, 3Days, but not 4Days (51±14
mmHg, 49±15 mmHg, 54±10 mmHg, 43±10 mmHg at 0Day, 2Days, 3Days and 4Days versus 27±6
mmHg in controls, p<0.05 for 0Day, 2Days, 3Days; Table 1). LVEDP rise, an indicator of
myocardial contracture, was lower in hearts from dipyridamole-treated animals compared to
controls at 0Day, 2Days, 3Days, but not 4Days (23±13 mmHg, 23±10 mmHg, 26±18 mmHg,
35±11 mmHg at 0Day, 2Days, 3Days and 4Days versus 52±24 mmHg in controls, p<0.05 for 0Day,
2Days, and 3Days; Table 1). These data suggest that dipyridamole therapy for 6 weeks improved
contractile recovery and reduced the degree of contracture or irreversible myocardial injury after
ischemia-reperfusion for at least 3 days after discontinuation of therapy. There were no differences
in coronary flow or coronary perfusion pressure before or after ischemia-reperfusion in
dipyridamole versus control hearts (Table 1).

This suggests that differences in coronary flow

cannot account for the improved contractile recovery after ischemia-reperfusion in hearts from
animals chronically treated with dipyridamole.

Regular Dipyridamole Therapy Reduces Infarct Size. Myocardial infarct size data are
shown in Figure 2. Myocardial infarct size in hearts from animals treated with dipyridamole were
significantly reduced by approximately 50% compared with control hearts at 0Day, 2Days, and
3Days, but not 4Days (22±12 %, 22±5 %, 22±6 %, 37±8 % at 0Day, 2Days, 3Days and 4Days
versus 42±5 %, controls, p<0.05 for 0Day, 2Days, and 3Days; Table 1).

Cardioprotection by Dipyridamole Persists After Discontinuation of Treatment: The effects of
discontinuing regular dipyridamole therapy on contractile recovery and infarct size after
ischemia-reperfusion are shown in Table 1 and Figure 2. Cardioprotection from chronic
dipyridamole treatment persisted for at least three days after discontinuation of treatment. By the
fourth day this cardioprotection began to dissipate, as evidenced by a non-significant improvement
in contractile functional recovery (LVEDP) and infarct size.

Persistent Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury is Associated
with Activated Akt and eNOS Expression: As shown in Figure 3, expression of activated Akt and
activated eNOS were elevated in hearts from dipyridamole-treated animals when compared to
control hearts. These increased expressions of activated Akt and activated eNOS persisted for at
least three days after discontinuation of dipyridamole treatment. These persistent expressions of
potential preconditioning mediators coincided with the time course after discontinuation of
dipyridamole treatment of decreased infarct size and improved hemodynamics following
ischemia-reperfusion.

DISCUSSION

The major finding of this study is that regular dipyridamole therapy produces sustained or chronic
protection against ischemia-reperfusion injury in guinea pig hearts that persists for at least 3 days
after discontinuing treatment. Furthermore, increased activated Akt and activated eNOS expression
coincide with this persistent cardioprotection and may play a role in mediating this chronic
preconditioning-like effect. There is currently no therapy available to induce chronic
cardioprotection against ischemia-reperfusion injury in patients at high risk for MI who may require
emergent reperfusion therapy.

Understanding the mechanisms underlying this persistent

cardioprotective effect of regular dipyridamole treatment may help in the development of therapies
to protect these at risk patients.

Acute dipyridamole therapy mimics ischemic preconditioning and has been shown to enhance the
protective effect of preconditioning against ischemia-reperfusion injury[9].

Acute exposure to

other nucleoside transport inhibitors, including dilazep[10] and ethanol[11], also mimic or enhance
the protective effect of ischemic preconditioning against ischemia-reperfusion injury.

We previously demonstrated that regular exposure to ethanol (daily for as little as 3 weeks), an
adenosine uptake inhibitor[12], produced sustained cardioprotection against ischemia-reperfusion
injury[5,6].

This preconditioning-like effect of regular ethanol treatment was attenuated in the

presence of selective adenosine A1 receptor antagonism[5].

Further, this ethanol-induced

cardioprotection persisted for at least seven days after discontinuing ethanol consumption[13].
Interestingly, epidemiological data are consistent with these observations; regular drinkers have
improved outcomes after acute MI when compared to abstainers[14,15].

Unfortunately, it is not

safe to recommend the cardioprotective effects of ethanol consumption given the risks for abuse and

alcoholic-related diseases.

Furthermore, ethanol, no doubt, has pleotropic effects beyond its

inhibition of adenosine reuptake, which may have detrimental effects on the heart, especially with
heavy consumption.

Therefore, we sought to determine whether regular dipyridamole therapy, a

safer adenosine uptake inhibitor, produced a similar chronic preconditioning-like effect[7].

Although the potential benefits of regular dipyridamole therapy in protecting against
ischemia-reperfusion injury have not been examined clinically, dipyridamole has been already
studied as potential therapy to reduce the risk of re-infarction in patients after MI[1].

In the

Persantine-Aspirin Reinfarction Study (PARIS), the efficacy of the combination of dipyridamole
and aspirin, aspirin alone, or placebo in preventing subsequent cardiac events in patients who had
previously suffered an MI was examined[1].

Dipyridamole and aspirin produced no statistically

significant additional benefit on total mortality, coronary mortality, or nonfatal MI compared to
aspirin alone (subgroup analysis did show that subjects less than 6 months from their previous MI
benefited from combination therapy). However, the PARIS trial was performed in the
pre-thrombolytic era.

In this era of emergent reperfusion therapies, potential chronic

preconditioning therapies require re-examination.

No therapy is yet available which produces a sustained preconditioned state.

Cohen and

colleagues reported that the cardioprotective effect of ischemic preconditioning in rabbits (40 to 65
five min occlusive episodes) waned after 3 to 4 days[16].

Dana et al., demonstrated that a

preconditioned state could be maintained in rabbits for at least 10 days using intermittent, not
continuous, infusion of an adenosine A1 agonist 2-chloro-N6-cyclopentyladenosine (CCPA)[17].
While activation of cardioprotection by regular dipyridamole therapy, intermittent CCPA or acute
ischemic preconditioning may be mediated similarly at the time of ischemia (e.g., via adenosine A1
receptor activation), chronic dipyridamole therapy may induce more lasting responses that produce

sustained protection which are not maintained by continued ischemic preconditioning.

For

example, we found that chronic exposure to ethanol causes sustained translocation and activation of
epsilon protein kinase C (εPKC) in myocytes[6], a PKC isozyme implicated in ischemic
preconditioning[18].

When regular treatment with an adenosine uptake inhibitor produces

sustained εPKC translocation to its site of activation[6], and εPKC is then triggered by the
adenosine A1 receptor signaling cascade at the time of ischemia, εPKC is already primed to open
sarcolemmal and mitochondrial adenosine triphosphate-sensitive potassium channels (mitoKATP),
shown to play a role in reducing infarct size in ischemic and ethanol preconditioning[11].

Cardiac myocytes express eNOS which regulates myocardial contractile function and oxygen
consumption[19]. Nitric oxide is an important mediator in cardioprotection, activating mitoKATP[20].
Knockout mice lacking eNOS suffer larger infarcts than wild type after ischemia[21].
Overexpression of eNOS in mice attenuates myocardial ischemia-reperfusion injury[22]. In our
study, increased activated eNOS expression coincided with the persistent dipyidamole-induced
cardioprotection for at least three days after discontinuation of therapy. We previously reported on
persistent cardioprotection by chronic ethanol consumption after abstention and the potential role of
activated eNOS in that persistent cardioprotection model[13].

Preventing mPTP opening by inhibiting glycogen synthase kinase 3β (GSK
(GSK-3β ) has been shown to
play a role in ischemic preconditioning[24]. Irreversible mPTP opening abolishes the mitochondrial
membrane potential, disabling ATP production. GSK-3β is a substrate for multiple pro-survival
protein kinases, including Akt. Inhibiting GSK-3β by PI3/Akt signaling is a key event in preventing
mPTP opening, increasing cell survival[25]. Zhong et al., reported that mice fed 18% ethanol in
their drinking water for 12 weeks demonstrated sustained translocation of ε -PKC, as well as
increased Akt expression[26]. In our study, increased activated Akt expression coincided with

persistent dipyidamole-induced cardioprotection for at least three days after discontinuation of
therapy.

There is currently no therapy available to induce sustained protection against ischemia-reperfusion
injury in patients at high risk for MI who may require emergent reperfusion therapy.
suggest

that

regular

dipyridamole

therapy

produces

sustained

protection

Our data
against

ischemia-reperfusion injury, lasting up to three days after discontinuation of treatment.
Furthermore, increased activated Akt and activated eNOS expression coincide with this persistent
cardioprotection and may play a role in mediating this chronic preconditioning-like effect. Future
studies will determine how chronic exposure to adenosine uptake inhibitors produce this delayed,
yet sustained, preconditioning state.
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FIGURE LEGENDS
Figure 1. Schematic illustration of experimental protocol. All hearts were subjected to 30 min of
global ischemia followed by 120 min of reperfusion. Dipyridamole-treated guinea pigs received 4
mg/kg/day dipyridamole in their drinking water for 6 weeks. Ischemia-reperfusion was performed at
0, 2, 3, and 4 days after discontinuation of dipyridamole (0Day, 2Days, 3Days and 4Days; n=8 for
each group). Tissue samples were obtained at baseline and 120 min after reperfusion (n=4 for each
group).

Figure 2. Infarct size as a percentage of the left ventricle. Myocardial infarct size was significantly
reduced in 0Day, 2Days and 3Days, but not 4Days, compared to control (22±12%, 21±5%, 22±6%,
37±8% at 0Day, 2Days, 3Days and 4Days versus control 42±5%, * p<0.05 for 0Day, 2Days,
3Days; n=8 for each group).

Figure 3. Western blot analyses of inducible endothelial nitric oxide synthase (eNOS) and Akt from
left ventricular samples in hearts from control and dipyridamole-treated animals. In the
dipyridamole group (except 4Days), expression of activated eNOS and Akt were significantly
increased compared with control at baseline (A) and after 120 min reperfusion (B). Data are
presented as mean±SD. * p<0.05 vs. CTL, n=4 for each group

Table 1.
Data are presented as mean±SD. * p<0.05 vs. CTL n=8 each group
LVDP = left ventricular developed pressure; LVEDP = left ventricular end-diastolic pressure; CF =
coronary flow
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